Document Detail

A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury.
MedLine Citation:
PMID:  19880667     Owner:  NLM     Status:  MEDLINE    
Several studies have recently demonstrated that G protein-coupled receptor 30 (GPER) can directly bind to estrogen and mediate its action. We investigated the role and the mechanism of estrogen-induced cardioprotection after ischemia-reperfusion using a specific GPER agonist G1. Isolated hearts from male mice were perfused using Langendorff technique with oxygenated (95% O(2) and 5% CO(2)) Krebs Henseleit buffer (control), with G1 (1 microM), and G1 (1 microM) together with extracellular signal-regulated kinase (Erk) inhibitor PD-98059 (5 microM). After 20 min of perfusion, hearts were subjected to 20 min global normothermic (37 degrees C) ischemia followed by 40 min reperfusion. Cardiac function was measured, and myocardial necrosis was evaluated by triphenyltetrazolium chloride staining at the end of the reperfusion. Mitochondria were isolated after 10 min of reperfusion to assess the Ca(2+) load required to induce mitochondria permeability transition pore (mPTP) opening. G1-treated hearts developed better functional recovery with higher rate pressure product (RPP, 6140 +/- 264 vs. 2,640 +/- 334 beats mmHg(-1) min(-1), P < 0.05). The infarct size decreased significantly in G1-treated hearts (21 +/- 2 vs. 46 +/- 3%, P < 0.001), and the Ca(2+) load required to induce mPTP opening increased (2.4 +/- 0.06 vs. 1.6 +/- 0.11 microM/mg mitochondrial protein, P < 0.05) compared with the controls. The protective effect of G1 was abolished in the presence of PD-98059 [RPP: 4,120 +/- 46 beats mmHg(-1) min(-1), infarct size: 53 +/- 2%, and Ca(2+) retention capacity: 1.4 +/- 0.11 microM/mg mitochondrial protein (P < 0.05)]. These results suggest that GPER activation provides a cardioprotective effect after ischemia-reperfusion by inhibiting the mPTP opening, and this effect is mediated by the Erk pathway.
Jean Chrisostome Bopassa; Mansoureh Eghbali; Ligia Toro; Enrico Stefani
Related Documents :
15249167 - Vasopressin effects on the coronary circulation after a short ischemia in anesthetized ...
3160757 - Regional wall motion improvement after coronary thrombolysis with recombinant tissue pl...
14633317 - Timing and duration of administration are crucial for antiinfarct effect of amp 579 inf...
8343327 - A patient in whom self-terminating ventricular fibrillation was a manifestation of myoc...
7641377 - Infarct salvage with liposomal prostaglandin e1 administered by intravenous bolus immed...
3473897 - The usefulness of echo-doppler in pediatric cardiology.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-10-30
Journal Detail:
Title:  American journal of physiology. Heart and circulatory physiology     Volume:  298     ISSN:  1522-1539     ISO Abbreviation:  Am. J. Physiol. Heart Circ. Physiol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-18     Completed Date:  2010-01-05     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  100901228     Medline TA:  Am J Physiol Heart Circ Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  H16-23     Citation Subset:  IM    
Division of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-7115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Triphosphate / physiology
Blotting, Western
Enzyme Inhibitors / therapeutic use
Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors,  physiology
Flavonoids / therapeutic use
Heart Diseases / prevention & control
Hemodynamics / physiology
Mice, Inbred C57BL
Mitochondria, Heart / physiology*
Myocardial Infarction / pathology
Myocardium / pathology*
Oxidative Stress / physiology
Protective Agents
Reperfusion Injury / pathology*
Reverse Transcriptase Polymerase Chain Reaction
Grant Support
Reg. No./Substance:
0/2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0/Enzyme Inhibitors; 0/Flavonoids; 0/Protective Agents; 56-65-5/Adenosine Triphosphate; EC Signal-Regulated MAP Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ischemic preconditioning and heat shock activate Akt via a focal adhesion kinase-mediated pathway in...
Next Document:  Nitric oxide is not obligatory for radial artery flow-mediated dilation following release of 5 or 10...